Some can­cer pa­tients now have to find oth­er op­tions as Bris­tol My­er­s' Abrax­ane falls in­to short­age from man­u­fac­tur­ing woes

When Beth Hogan, a metasta­t­ic pan­cre­at­ic can­cer pa­tient, showed up for her in­fu­sion at Yale’s Smilow Can­cer Hos­pi­tal in New Haven, CT on Oct. 11, she said she was in­formed that day that she would not be re­ceiv­ing Bris­tol My­ers Squibb’s Abrax­ane, part of her com­bo treat­ment, be­cause of a short­age.

“I was told we don’t know when you can have it,” she told End­points News via email, adding that she doesn’t ex­pect to re­ceive any Abrax­ane this com­ing Mon­day at her treat­ment ap­point­ment ei­ther, and she doesn’t know when things will change.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER